Sajad Zalzala, MD - What Patients Need to Know About Telemedicine (2019 Conference) (LDN, low dose naltrexone)

Sajad Zalzala, MD discusses what telemedicine is, its use and benefits, and about using LDN Direct telemedicine/LDN prescription business. Some telemedicine regulations are presented, as well as common conditions treated with LDN

LDN 2019 Conference - Friday Afternoon Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

Pamela Smith, MD - LDN Use in Cognitive Decline, Lyme Disease, and Hashimoto’s Thyroiditis (2019 Conference) (LDN, low dose naltrexone)

Pamela Smith, MD - LDN and Multiple Sclerosis (2019 Conference) (LDN, low dose naltrexone)

Nasha Winters, ND - Quelling the side effects of immune therapies with LDN (2019 Conference) (LDN, low dose naltrexone)

Mona Morstein, ND - Using Low Dose Naltrexone To Help SIBO Patients (2019 Conference) (LDN, low dose naltrexone)

Michael Ruscio, DC - The Gut-Thyroid Connection, Profound but Under-Appreciated (2019 Conference) (LDN, low dose naltrexone)

Leonard Weinstock, MD - Mast cell activation syndrome and potential role for LDN (2019 Conference) (LDN, low dose naltrexone)

Leonard Weinstock, MD discusses LDN  for MCAS and SIBO at the LDN 2019 Conference. He discusses the etiology, symptoms, testing, and therapy for MCAS, SIBO, and POTS; and presents related cases.
 

Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD - Causes of Hashimoto's (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD discusses Hasimoto’s thyroiditis at the LDN 2019 Conference. He discusses the mechanisms of thyroid dysfunction, causes and evaluation of Hashimoto’s thyroiditis, Hashimoto’s in obesity, and treatments of Hasimoto's